Abstract
Recent trials have demonstrated that onabotulinumtoxinA is a safe and effective treatment for the prevention of chronic migraine headaches. Although the exact effect of the toxin on the pathophysiology of migraine is not clear, several in-vivo and in-vitro models have shown that onabotulinumtoxinA inhibits the release of neurotransmitters and neuropeptides involved in pain signaling pathways with resulting attenuation of both peripheral and central sensitization in migraine. Limited systemic adverse effects and physician administered treatments that eliminate concerns for patient compliance have made onabotulinumtoxin A an appealing alternative to oral prophylactic medications for migraine. This article is designed to provide an overview of current research into the mechanism of action of onabotulinumtoxinA in the pathophysiology of pain conditions including migraine, as well the current literature supporting its efficacy in migraine treatment.
In the 1820s, Justinus Kerner described the clinical syndrome of botulism as a foodborne illness after compiling 76 cases of lethal food poisoning that occurred following the ingestion of spoiled smoked sausages 1 . He isolated an extract that contained the purported toxin from the sausages and characterized its effects on animal models. His published reports proposed that the isolated toxin had potential therapeutic uses 1 . Kerner's ideas, though visionary, were not fully realized until the late 1970s, when ophthalmologist Alan Scott used onabotulinumtoxinA for the treatment of strabismus and blepharospasm 2 .
Today, onabotulinumtoxinA (BoNT-A) is used in the management of several medical conditions, including dystonia, blepharospasm, and spasticity, and is the only FDA-approved medication for the prevention of chronic migraines. The observation of therapeutic benefit of BONT-A in the treatment of pain has incited research into the mechanism of action of BoNT-A outside of the neuromuscular junction. Although the pathophysiology is still not well understood, the use of BoNT-A in the prevention of chronic headaches, specifically chronic migraine, has proven to be an effective treatment modality, with few contraindications and minimal side effects.
Effect of Onabotulinumtoxin A on Cholinergic Neurons
The effect of BoNT-A on the neuromuscular junction is well described. When injected into the target muscle, the C-terminal of the heavy chain binds to ganglioside acceptor protein on the plasma membrane of the alpha motor neuron and mediates endocytosis of the toxin 3 As the clinical use of BoNT-A increased following Dr. Scott's work in strabismus, providers made a number of curious observations about the effects of the medication after it was injected for involuntary movements. Reports included descriptions of bilateral and distant effects after unilateral injection for spasticity and dystonia, decrease in muscle spasm strength and muscle spasm frequency, and alleviation of sensory symptoms, such as neck tenderness in spasmodic torticollis and light sensitivity in blepharospasm 6 . Giladi cites a number of examples where the improvements in sensory symptoms were disproportionate to the degree of muscle weakness or outlasted the duration of muscle weakness 6 . These observations suggested that
BoNT-A had effects in addition to those on motor neurons.
A possible explanation for the effect on neurons distal to the injection site was proposed after it was shown that onabotulinumtoxinA undergoes retrograde transport in motor neurons 7 .
Antonucci et al. demonstrated BoNT-A truncated SNAP-25 at distal projections from both peripheral and central BoNT-A injections. The transport of SNAP-25 was inhibited by colchicine, indicating microtubule-dependent axonal transport. BoNT-A also inhibits gammamotor neurons innervating intrafusal fibers in muscle spindles 8 . Information about muscle stretch is transmitted from muscle spindles to the CNS via 1a afferents. It has been proposed there is some degree of pain relief from the resulting reduction in afferent input of tonic muscle contractions 9 . However, it is difficult to extrapolate this hypothesis to the mechanism of action of
BoNT-A on headache because facial muscles contain very few muscle spindles 6 .
BoNT-A inhibits cholinergic neurotransmission in the autonomic nervous system.
Several neurotransmitters and neuropeptides, including enkephalins, substance P, neurotensin, somatostatin, ATP, vasoactive intestinal protein (VIP) , neuropeptide Y, and NO, co-localize with ACh in autonomic neurons 10, 11 . BoNT-A may inhibit the release of substances other than
ACh that are released through a common vesicular docking mechanism 12 . Some authors also postulate that the inhibition of autonomic transmission by BoNT-A may suppress neurogenic 
Clinical Results of OnabotulinumtoxinA in the Prevention of Episodic Migraine
Although initial results on the use of BoNT-A in the treatment of episodic migraine were positive, subsequent trials failed to show a significant improvement in migraine frequency or severity. In the first study following Binder and colleagues' initial observations, 123 subjects with 2 to 8 migraines/month were randomized to placebo, 25U, or 75U BoNT-A. Injections sites included bilateral frontalis, temporalis, procerus, and corrugator muscles. There was a significant decrease in migraines/month in the 25U but not the 75U group, compared with placebo. The lack of effect in the higher-dose group was attributed to lower mean migraine frequency in the baseline group characteristics; 4.3 in the 25U group compared with 4.0 in the 75U group 21 .
Subsequently, Evers et al evaluated differences in response to frontal versus neck muscle injection sites. Sixty-six subjects with 2 to 8 migraines/month were randomized to either 100U in the frontalis, temporalis, SCM, trapezius, splenius capitus, and semispinalis, or 16U in the frontalis and temporalis and placebo in the neck muscles, or placebo in all muscle groups. There was no significant difference in migraine frequency among the three treatment groups. However, there was a significant decrease in migraine-associated symptoms in the 16U, but not the 100U, treatment group 22 .
Elkind et al evaluated 418 subjects with 4 to 8 migraines/month in three sequential four month trials with re-randomization at each stage. Subjects were treated with 7.5U, 25U, or 50U
BoNTA. There were no significant differences in migraine frequency between the two groups 23 .
Aurora et al evaluated the "follow-the-pain" injection protocol in episodic migraine.
Fixed-dose injections were given in the occipitalis, with the remainder of the injections and doses chosen based on the severity and distribution of the subject's pain rather than fixed doses in predetermined muscles (the "fixed-site, fixed-dose" paradigm). The study randomized 369 subjects with ≥ 4 migraines but ≤ 15 headache days/month to three treatments with 110 to 260U
BoNTA or placebo every 90 days. There was no statistically significant difference between the two groups. However, subgroup analysis of subjects with a baseline migraine frequency of ≥ 12
headache days/month did show a significant decrease in headache episodes compared with placebo at the Day 180 endpoint, -4 versus -1.9 (p=0.48) 24 .
In an effort to better characterize BoNTA responders with episodic migraine, Relja et al divided subjects into placebo responders (n=173) and placebo nonresponders (n=322) and then randomized to 75, 150 or 225U BoNTA or placebo every 90 days for 6 months. Subjects on concomitant preventive migraine medications were excluded. Injections were fixed-site, fixeddose into the frontalis, corrugator, temporalis, trapezius, splenius capitus, semispinalis, and occipitalis muscles. There was no significant difference in headache frequency between the two groups at the Day 180 primary endpoint 25 .
Saper et al evaluated the effect of different injection sites and dosing amounts in 232
subjects with 4 to 8 migraines/month. Subjects were randomized to four different injection site patterns: frontalis (10U), temporalis (6U), glabellar (9U), or all three sites combined (25U).
There was no significant difference in headache frequency at the Day 60 primary endpoint 26 . The authors supposed that one of the reasons for the negative results may have been due to the low doses of BoNT-A.
Clinical Results of OnabotulinumtoxinA in the Prevention of Chronic Daily Headache and Chronic Migraine
While the aforementioned authors were evaluating the efficacy of BoNT-A in episodic migraine, Mathew et al. reported a positive outcome in a heterogeneous patient population with chronic daily headache (CDH) 27 . CDH is a broad category that includes any primary headache disorder that occurs with a frequency of 15 days/month or more. In this randomized, doubleblind, placebo-controlled trial, 355 subjects with headache ≥ 15 days/month were divided into placebo responders (n=76) and nonresponders (n=279) and treated with 105 to 260U in a "follow-the-pain" distribution every 90 days for three treatment cycles. Although there was no significant difference for the primary endpoint of the number of headache-free days at Day 180, there were significant differences in several secondary endpoints. The BoNTA treatment group had a larger percentage of subjects with a ≥50% reduction in headache frequency and a greater mean change from baseline headache frequency at Day 180 27 . A subgroup analysis that excluded subjects taking preventive migraine medication found that the BoNTA treatment group had a statistically significant decrease in headache frequency compared to placebo after the second and third treatments 28 shown to be safe and well tolerated 30, 31, 32 .
Comparative Efficacy of OnabotulinumtoxinA in Chronic Migraine
A few trials have been conducted that compared the effectiveness of BoNT-A to oral medication in migraine headache prevention . Mathew et al randomized 60 CM patients to either
BoNT-A (100U fixed-site and 100 U follow-the-pain) and oral placebo or topiramate and placebo injections. Subjects received two rounds of injections at study start and month 3, whereas the topiramate group continued medication until study completion at 9 months. Only 36 subjects completed the study: 24.1% in the topiramate group dropped out due to adverse effect compared with 7.7% in the BoNT-A group. At the 9 month endpoint, a similar number of patients reported a ≥50% decrease in headache/migraines days in the BoNT-A and topiramate groups, 40.9% and 42.9% respectively 33 . Cady et al also evaluated BoNT-A to topiramate in a randomized, double-blind, placebo-controlled study of 59 CM patients over 12 weeks 34 . There was significant reduction in the number of headache days per month within but not between the two groups.
A trial of 59 patients randomized to 100U BoNT-A and oral placebo or 250mg divalproex sodium BID and placebo injections showed similar improvement in migraine disability and reduction in headache days. There were a greater percentage of adverse effects and discontinuation in the divalproex group 35 . Another study of CM patients showed that treatment with 250U BoNT-A had similar efficacy as 25mg or 50mg amitriptyline 36 .
These studies suggest that BoNT-A has similar efficacy and a superior side effect profile compared to available oral medications for prevention of CM. Physician-administered injections every three month also reduce concerns for compliance with a daily dosing regimen.
Techniques for Onabotulinumtoxin-A Injection in the Prevention of Chronic Migraine
The injection protocols commonly used are: (1) the fixed-site, fixed-dose approach, which uses fixed, symmetrical injection sites and predetermined doses; (2) the follow-the-pain approach, which often employs asymmetrical injections and adjusts the sites and doses depending on where the patient feels pain and where the examiner can elicit pain and tenderness on palpation of the muscle; and (3) a combination approach, which uses injections at fixed frontal sites, supplemented with follow-the-pain injections (this approach typically uses higher doses of BoNT-A) 37 .
The PREEMPT clinical trials used a modified follow-the-pain injection paradigm 30, 31 .
OnabotulinumtoxinA (155 U) was administered as 31 fixed-site, fixed-dose injections across seven specific head and neck muscle areas using a sterile 1 ml Luer Lock syringe with a 30- (B) The first of the 3 trapezius muscle injection sites is located in the lateral aspect of the muscle.
The second site is within the mid-portion of the muscle and the third site is within the superior aspect of the muscle. Symmetrical injections should be repeated on the contralateral side for a total of 6 injections. Up to 4 additional injections can be distributed between the right and left trapezius muscles, in the areas identified as having maximal tenderness.
